Novel Benzohydroxamate-Based Potent and Selective Histone Deacetylase 6 (HDAC6) Inhibitors Bearing a Pentaheterocyclic Scaffold: Design, Synthesis, and Biological Evaluation

J Med Chem. 2019 Dec 12;62(23):10711-10739. doi: 10.1021/acs.jmedchem.9b01194.

Barbara Vergani ¹, Giovanni Sandrone ¹, Mattia Marchini ¹, Chiara Ripamonti ¹, Edoardo Cellupica ¹, Elisabetta Galbiati ¹, Gianluca Caprini ¹, Gianfranco Pavich ¹, Giulia Porro ¹, Ilaria Rocchio ¹, Maria Lattanzio ¹, Marcello Pezzuto ¹, Malgorzata Skorupska ¹, Paola Cordella ¹, Paolo Pagani ¹, Pietro Pozzi ¹, Roberta Pomarico ¹, Daniela Modena ¹, Flavio Leoni ¹, Raffaella Perego ¹, Gianluca Fossati ¹, Christian Steinkühler ¹, Andrea Stevenazzi ¹

Affiliations

Affiliation

1 Preclinical R&D , Italfarmaco Group , Via dei Lavoratori 54 , I-20092 Cinisello Balsamo , Milan , Italy.

PMID: 31710483 DOI: 10.1021/acs.jmedchem.9b01194

Abstract

Histone deacetylase 6 (HDAC6) is a peculiar HDAC isoform whose expression and functional alterations have been correlated with a variety of pathologies such as autoimmune disorders, neurodegenerative diseases, and Cancer. It is primarily a cytoplasmic protein, and its deacetylase activity is focused mainly on nonhistone substrates such as tubulin, heat shock protein (HSP)90, Foxp3, and cortactin, to name a few. Selective inhibition of HDAC6 does not show cytotoxic effects in healthy cells, normally associated with the inhibition of Class I HDAC isoforms. Here, we describe the design and synthesis of a new class of potent and selective HDAC6 inhibitors that bear a pentaheterocyclic central core. These compounds show a remarkably low toxicity both in vitro and in vivo and are able to increase the function of regulatory T cells (Tregs) at well-tolerated concentrations, suggesting a potential clinical use for the treatment of degenerative, autoimmune diseases and for organ transplantation.

Name
Email *

	Sorry, but the email address you supplied was invalid.